Are more immuno-oncology buyouts on the menu at Eli Lilly’s executive suite?
Flush with cash following the Elanco spinoff, Eli Lilly execs are talking up the chances of executing more near-term buyouts like their $1.6 billion Armo …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
